<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Irinotecan; Topotecan" /><meta name="IX" content="Irinotecan; Topotecan" /><title>Topoisomerase I inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5566-topoisomerase-i-inhibitors.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5566-topoisomerase-i-inhibitors.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5566-topoisomerase-i-inhibitors.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5562-paclitaxel.htm" title="Previous: PACLITAXEL">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5568-irinotecan-hydrochloride.htm" title="Next: IRINOTECAN HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a396034.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan Hydrochloride</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a397006.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Topotecan Hydrochloride</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/15278-p.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Irinotecan</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: I &gt; Interactions of Irinotecan</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/17159-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Topotecan</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: T &gt; Interactions of Topotecan</p></div></li></ul><ul><li><h3>British National Formulary (7)</h3></li><li><a href="PHP5487-platinum-compounds.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Platinum compounds</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs</p></div></li><li><a href="PHP5568-irinotecan-hydrochloride.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">IRINOTECAN HYDROCHLORIDE</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Topoisomerase I inhibitors</p></div></li><li><a href="PHP5569-irinotecan-non-proprietary.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Topoisomerase I inhibitors &gt; IRINOTECAN HYDROCHLORIDE</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22irinotecan%22%22topotecan%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (7)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK0894.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; I</p></div></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1635.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Topotecan</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; T</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a597013.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan Hydrochloride</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; I</p></div></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a500007.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Topotecan Hydrochloride</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0009s0097.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan Hydrochloride</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; I</p></div></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0019s0285.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Topotecan</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/19006-c.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan Hydrochloride</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/15104-s.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Topotecan Hydrochloride</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/05091.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; I &gt; IR</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/09548.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Topotecan</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; T &gt; TO</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c113-sec1-003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Practice Considerations</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 2: The Practice of Pharmacy &gt; Section 10: Patient Care &gt; 113 Pharmacogenomics in Pharmacy Practice</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-I80.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Irinotecan Hydrochloride Trihydrate</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; I</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-T108.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Topotecan Hydrochloride</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; T</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22irinotecan%22%22topotecan%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>Stockley's Drug Interactions (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E2E3E0R0D714.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Irinotecan</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; I</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E2E3E0R0D1652.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Topotecan</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; T</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><?highlighter on?><h1>Topoisomerase I inhibitors</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p>Irinotecan and topotecan inhibit topoisomerase I, an enzyme involved in DNA replication.</p> <p><strong>Irinotecan</strong> is licensed for metastatic colorectal cancer in combination with fluorouracil and folinic acid or as monotherapy when treatment containing fluorouracil has failed. It is also licensed in combination with cetuximab for the treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer after failure of chemotherapy that has included irinotecan. Irinotecan is also licensed in combination with fluorouracil, folinic acid and bevacizumab for the first-line treatment of metastatic carcinoma of the colon or rectum. Irinotecan is also licensed in combination with capecitabine with or without bevacizumab for the first-line treatment of metastatic colorectal carcinoma. Irinotecan is given by intravenous infusion.</p> <div class="cI"><h3 class="cT">NICE guidance (irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer)</h3><p>See section 8.1.5, <a title="target-block: NICE: irinotecan" href="PHP5487-platinum-compounds.htm#PHP5494">Platinum compounds</a></p></div> <p><strong>Topotecan</strong> is given by intravenous infusion or orally in relapsed small-cell lung cancer when retreatment with the first-line regimen is considered inappropriate. Topotecan injection is also licensed for metastatic ovarian cancer when first-line or subsequent treatment has failed. Topotecan injection is licensed in combination with cisplatin for treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB disease.</p> <p id="PHP5567">In addition to dose-limiting myelosuppression, side-effects of irinotecan and topotecan include gastro-intestinal effects (delayed diarrhoea requiring prompt treatment may follow irinotecan treatment), asthenia, alopecia, and anorexia.</p> <p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (November 2007) that topotecan (<em>Hycamtin</em>®) is accepted for restricted use in combination with cisplatin for treatment of recurrent carcinoma of the cervix after radiotherapy and for stage IVB disease; it is restricted to patients who have not previously received cisplatin treatment.</p> <p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (March 2009) that use of topotecan capsules within NHS Scotland is restricted to patients in whom standard intravenous chemotherapy is inappropriate and who would otherwise receive best supportive care.</p> <div id="PHP19111" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009)</h3><p>Topotecan in combination with cisplatin is recommended as a treatment option for recurrent or stage IVB cervical cancer in patients who have not previously received cisplatin.</p><p><a href="http://www.nice.org.uk/TA183">www.nice.org.uk/TA183</a></p></div> <div id="PHP19112" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)</h3><p>Oral topotecan is recommended as an option for treatment in patients with relapsed small-cell lung cancer only if re-treatment with the first-line regimen is not considered appropriate, and the combination of cyclophosphamide, doxorubicin and vincristine is contra-indicated. Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.</p><p><a href="http://www.nice.org.uk/TA184">www.nice.org.uk/TA184</a></p></div> <div class="cI"><h3 class="cT">NICE guidance (paclitaxel, pegylated liposomal doxorubicin and topotecan for second-line or subsequent treatment of advanced ovarian cancer)</h3><p>See <a title="target-block: paclitaxel, doxorubicin, topotecan nice guidance" href="PHP5487-platinum-compounds.htm#PHP5496">Platinum Compounds</a></p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5568-irinotecan-hydrochloride"><a href="PHP5568-irinotecan-hydrochloride.htm" title="IRINOTECAN HYDROCHLORIDE">IRINOTECAN HYDROCHLORIDE</a></li><li id="_PHP5571-topotecan"><a href="PHP5571-topotecan.htm" title="TOPOTECAN">TOPOTECAN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5562-paclitaxel.htm">Previous: PACLITAXEL</a> | <a class="top" href="PHP5566-topoisomerase-i-inhibitors.htm#">Top</a> | <a accesskey="]" href="PHP5568-irinotecan-hydrochloride.htm">Next: IRINOTECAN HYDROCHLORIDE</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>